AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 5th, 2021 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 5th, 2021 Company Industry JurisdictionTHIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and Raj Krishnan, Ph.D. (“Executive”), and shall be effective as of January 6, 2021 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 5th, 2021 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 5th, 2021 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and Chase Leavitt (“Executive”), and shall be effective as of April 12, 2021 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 5th, 2021 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 5th, 2021 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and Salim Yazji (“Executive”), and shall be effective as of May 17, 2021 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 8th, 2019 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledNovember 8th, 2019 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and Frank Hsu, M.D. (“Executive”), and shall be effective as of August 26, 2019 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 8th, 2019 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledNovember 8th, 2019 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and Richard Vincent (“Executive”), and shall be effective as of September 12, 2019 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 8th, 2019 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledNovember 8th, 2019 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and Igor Bilinsky, Ph.D. (“Executive”), and shall be effective as of September 9, 2019 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 8th, 2019 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledNovember 8th, 2019 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and Gunnar Kaufmann, Ph.D. (“Executive”), and shall be effective as of September 5, 2019, or such earlier date as mutually agreed, (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 8th, 2019 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledNovember 8th, 2019 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and James B. Breitmeyer, M.D, Ph.D. (“Executive”), and shall be effective as of September 12, 2019 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 8th, 2019 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledNovember 8th, 2019 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and Hazel M. Aker (“Executive”), and shall be effective as of September 12, 2019 (the “Effective Date”).